Nephrotic Syndrome Market Report 2026

Nephrotic Syndrome Market Overview

• Nephrotic Syndrome market size has reached to $0.96 billion in 2025 • Expected to grow to $1.58 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: Rising Incidence Of Kidney Diseases Driving Growth In The Market • Market Trend: Innovative Formulations Drive Advancements In The Market • North America was the largest region in 2025.

What Is Covered Under Nephrotic Syndrome Market?

Nephrotic syndrome is a kidney disorder characterized by excessive protein loss in the urine (proteinuria), low levels of protein in the blood (hypoalbuminemia), high cholesterol levels (hyperlipidemia), and swelling (edema), especially in the legs, feet, and around the eyes. It occurs due to damage to the glomeruli, the kidney's filtering units, which allows the protein to leak into the urine. The main types of nephrotic syndrome are drugs and devices. Drugs are substances used to diagnose, treat, or prevent diseases by modifying body functions. Nephrotic syndrome can be diagnosed through various tests, including urinalysis, glomerular filtration rate (GFR) measurement, blood tests, kidney biopsy, and computerized tomography (CT) scans. The key applications include clinics, hospitals, specialty centers, and other healthcare facilities.

What Is The Nephrotic Syndrome Market Growth Forecast?

The nephrotic syndrome market size is expected to see rapid growth in the next few years. It will grow to $1.58 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to advancements in targeted therapies, increasing use of precision nephrology, development of improved dialysis devices, rising investment in kidney replacement therapy innovations, growing adoption of molecular diagnostic tools. Major trends in the forecast period include rising use of immunosuppressive therapies, growing demand for advanced dialysis and kidney support devices, increasing adoption of early diagnostic screening programs, higher prevalence of chronic kidney diseases driving treatment needs, expansion of personalized medicine approaches in nephrology.

Global Nephrotic Syndrome Market Segmentation

1) By Type: Drugs, Devices 2) By Diagnosis Tests: Urinalysis, Glomerular Filtration Rate (GFR), Blood Test, Kidney Biopsy, Computerized Tomography (CT) Scan 3) By Application: Clinics, Hospitals, Specialty Centres, Other Applications Subsegments: 1) By Drugs: Steroids, Immunosuppressants, Diuretics, ACE Inhibitors 2) By Devices: Dialysis Machines, Peritoneal Dialysis Catheters, Hemodialysis Catheters, Kidney Replacement Therapy Devices

What Is The Driver Of The Nephrotic Syndrome Market?

The increasing incidence of kidney diseases is expected to propel the growth of the nephrotic syndrome market going forward. Kidney diseases refer to any conditions or disorders impairing the kidneys' function, which are vital organs responsible for filtering waste and excess fluids from the blood. The increasing incidence of kidney diseases is attributed to factors such as diabetes, hypertension, obesity, aging populations, and lifestyle changes, including high sodium intake and inadequate hydration. Nephrotic syndrome contributes to kidney diseases by causing damage to the glomeruli, impairing the kidney's ability to filter waste and retain essential proteins. For instance, in June 2023, according to the Oxford Academic, a UK-based Oxford University Press's academic research platform, the prevalence of CKD in the UK is projected to rise by 4% from 8.27 million to 8.61 million people between 2022 and 2032, with stage distribution in 2032 expected at 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Therefore, the increasing incidence of kidney diseases is driving the growth of the nephrotic syndrome industry.

Key Players In The Global Nephrotic Syndrome Market

Major companies operating in the nephrotic syndrome market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Eli Lilly and Company, Asahi Kasei Corporation, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals, Chugai Pharmaceutical Co. Ltd., Mallinckrodt Company, Evotec SE, Travere Therapeutics Inc., Aurinia Pharmaceuticals Inc., Orbis Biosciences Inc., Alpine Immune Sciences, Kezar Life Sciences, Zenyaku Kogyo Co. Ltd

Global Nephrotic Syndrome Market Trends and Insights

Major companies operating in the nephrotic syndrome market are focusing on developing innovative formulations, such as loop diuretic injections, to improve fluid management and reduce edema in nephrotic syndrome patients. Loop diuretic Injection refers to an injectable medication that inhibits sodium and chloride reabsorption in the loop of Henle, promoting rapid urine production. It is used to treat conditions such as acute pulmonary edema, heart failure, and severe hypertension by reducing fluid overload. For instance, in March 2024, Avenacy Inc., a US-based pharmaceutical company, launched furosemide for Injection in the U.S., a generic equivalent to Lasix, approved by the Food and Drug Administration for treating edema related to heart failure, liver cirrhosis, and kidney diseases. Packaged in 25-unit packs of 100 mg/10 mL doses, this launch is part of Avenacy's broader strategy to expand its injectable medication portfolio, with plans to launch over 20 products in 2024. This drug is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.

What Are Latest Mergers And Acquisitions In The Nephrotic Syndrome Market?

In August 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired Chinook Therapeutics for $3.5 billion. With this acquisition, Novartis aims to expand its renal portfolio by integrating Chinook Therapeutics’ late-stage assets, atrasentan, and zigakibart, which are in development for the treatment of Immunoglobulin A Nephropathy (IgAN), aligning with its strategy to focus on innovative medicines. Chinook Therapeutics is a US-based biopharmaceutical company that developed medicines for nephrotic syndrome.

Regional Outlook

North America was the largest region in the nephrotic syndrome market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nephrotic Syndrome Market?

The nephrotic syndrome market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, dialysis services, and kidney transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nephrotic syndrome market also includes sales of diuretics, anticoagulants, immunosuppressants, ACE inhibitors and Arbs and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nephrotic Syndrome Market Report 2026?

The nephrotic syndrome market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nephrotic syndrome industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.